Last updated on August 2019

Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort Turbuhaler in Patients With Chronic Obstructive Pulmonary Disease ( COPD)


Brief description of study

The purpose of this study is to demonstrate the superiority of CHF 5993 pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) over Symbicort Turbuhaler in terms of pulmonary function, as well as to assess its safety.

Clinical Study Identifier: NCT03197818

Find a site near you

Start Over

Chiesi Clinical Trial Site 410003

Chuncheon, Korea, Republic of
  Connect »

Chiesi Clinical Trial Site 410012

Bucheon-si, Korea, Republic of
  Connect »

Chiesi Clinical Trial Site 410002

Goyang-si, Korea, Republic of
  Connect »

Chiesi Clinical Trial Site 410009

Gyeonggi-do, Korea, Republic of
  Connect »